Climate Change Data

Environmental Metrics

ESG Focus Areas

• Commitment to patients
• Responsible behaviour

Environmental Achievements

• 80% renewable energy in Sobi operations

Social Achievements

• Launched florio ITP, a digital diary for patients with ITP in the US in partnership with PDSA (Platelet Disorder Support Association)
• 95% completed Code of Conduct training
• Continued support for the WFH (World Federation of Hemophilia) Humanitarian Aid Program

Governance Achievements

• Launched a new, updated Code of Conduct
• Extended the whistleblower hotline to include external parties
• Established a Corporate Compliance Committee

Climate Goals & Targets

Environmental Challenges

• Competitive challenges in most markets for Elocta and Alprolix
• Failure to reach agreement on reimbursement in France for Doptelet
• Generic competition impacting Orfadin sales
• COVID-19 pandemic affecting employee health and operations
• Conflict in Ukraine impacting operations in Russia

Mitigation Strategies

• Take Control campaign to encourage patients to return to higher factor levels
• Global omnichannel marketing project for Doptelet launched in early 2022
• Promoting working from home and limiting international travel
• Closely monitoring events in Ukraine to assess potential risks
• Responsible Sourcing Programme to ensure supplier compliance with ethical, human rights, and environmental standards

Supply Chain Management

Supplier Audits: 75% of suppliers reporting in EcoVadis performed audits or assessments of suppliers on CSR issues

Responsible Procurement

• Partner Code of Conduct
• Supplier risk assessment and qualification
• Performance management and monitoring
• Membership in Pharmaceutical Supply Chain Initiative (PSCI)
• Use of EcoVadis sustainability reporting platform

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GRI

Environmental Metrics

ESG Focus Areas

• Patient commitment
• Responsible actions

Environmental Achievements

• 83% renewable energy in Sobi operations
• Completed mapping of Scope 3 emissions

Social Achievements

• Launched company-wide DEI initiative
• Increased access to medicines to approximately 75,000 full-time equivalent patients
• Donated SEK 1M to the Red Cross in Sweden to support relief efforts in Ukraine
• 97% of eligible employees completed Code of Conduct training

Governance Achievements

• Implemented new global operating procedure governing compliance monitoring and self-inspections
• Launched updated global Investigations policy in accordance with the EU Whistleblowing Directive
• 12 compliance cases reported and investigated

Climate Goals & Targets

Environmental Challenges

• Significant geopolitical and macroeconomic uncertainty
• Fundamental societal challenges
• Competition in the market
• Reduced sales in COVID-19 treatment
• Generic competition to Orfadin and fewer people treated with Tegsedi
• War in Ukraine affecting access to markets in Russia and Ukraine

Mitigation Strategies

• Efficiency programmes (discontinuation of contract manufacturing, site consolidation, restructuring of functions)
• Value-based pricing model
• Close collaboration with stakeholders
• Good relationships with supplier networks, close monitoring and maintenance of stock levels
• Contingency plans including dual sourcing and multiple suppliers
• Responsible sourcing programme
• Closely following the situation in Ukraine to comply with rules and regulations and assess risks

Supply Chain Management

Supplier Audits: 75% of contract manufacturers reporting in EcoVadis

Responsible Procurement

• Responsible Sourcing Programme
• Partner Code of Conduct
• EcoVadis sustainability reporting platform

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GRI Standards 2021, TCFD, EU Taxonomy

Third-party Assurance: Ernst & Young AB

Environmental Metrics

ESG Focus Areas

• Patient commitment
• Responsible actions

Environmental Achievements

• 76% of all electricity consumed originates from certified renewable energy sources.

Social Achievements

• Company-wide DEI initiative further deployed; Global employee engagement survey showed improvement from 69 to 73 points; Established four international patient councils to advise on early clinical development; Trained 525 employees in patient-centric practices; Continued partnership with EUPATI and PFMD; Supported WFH Humanitarian Aid Program.
• 95% of eligible Sobi employees completed Code of Conduct training; 91% completed anti-corruption and anti-bribery training

Governance Achievements

• Updated Anticorruption policy and launched new training; 14 compliance cases reported and investigated; New global operating procedure governing compliance monitoring and self-inspections in place; Updated global Investigations policy launched in accordance with the EU Whistleblowing Directive

Climate Goals & Targets

Environmental Challenges

• Supply chain disruptions due to geopolitical instability and climate change; Competition in the market; Price pressure; Regulatory hurdles; Access to treatment; Maintaining high standards in new countries and with new employees; Ensuring patient safety; Managing risks related to third parties; Information and cybersecurity incidents; Workforce vacancies; Financial risks (currency, interest rate, liquidity, credit); Impairment of assets; Tax complexities; Sustainability reporting requirements; Litigation and other claims; IP protection; Compliance issues.

Mitigation Strategies

• High focus on existing medicines, acquisition strategy, licensing and royalty agreements; Quality management systems, regulatory compliance, close management of clinical studies; Value-based pricing models, monitoring of healthcare systems; Collaboration with stakeholders, participation in the European Pharmaceutical Strategy; Good relationships with supply chain partners, monitoring of stock levels, contingency plans, dual sourcing; Third-party risk management program, Responsible Sourcing Programme; Group-wide information and cybersecurity framework, training; Good working conditions, leadership development, DEI focus, employee surveys; Robust processes and systems for patient safety, pharmacovigilance; Financial risk management strategies, impairment testing; Tax compliance processes, collaboration with advisors; Taskforce for CSRD implementation; Regulatory compliance, R&D and pharmacovigilance processes, insurance programs; Active management of IP rights, IP litigation; Compliance framework, governance systems, training, whistleblowing system.

Supply Chain Management

Supplier Audits: 100% of contract manufacturers reporting in EcoVadis

Responsible Procurement

• Partner Code of Conduct
• EcoVadis platform
• PSCI membership

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GRI Standards 2021, TCFD, EU Taxonomy

Third-party Assurance: Ernst & Young AB

UN Sustainable Development Goals

• Goal 3: Good Health and Well-being

Improving the lives of people with rare diseases